News

Amicus Therapeutics announced it is establishing a new Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia, PA, to advance its commitment to…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced positive results from the Phase III POLO trial. Results from…
Read More...

Imbrium Therapeutics and TetraGenetics announced a strategic research & development collaboration to utilize TetraGenetics’ antibody discovery technology platform (TetraExpress) in…
Read More...

Selexis SA and Turgut Pharmaceuticals (Turgut Ilaclari A.S.) announced that they have signed two commercial license agreements (CLAs) through which Turgut will leverage Selexis’…
Read More...

Amgen, Cytokinetics, Incorporated and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in…
Read More...

Urovant Sciences announced it has entered into a debt financing agreement with Hercules Capital for up to $100 million. Urovant plans to use the proceeds to fund ongoing development of…
Read More...

Ipsen and Clementia Pharmaceuticals announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage clinical asset…
Read More...

Novartis announced that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea…
Read More...

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a…
Read More...

AbbVie and Voyager Therapeutics announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological…
Read More...

Mallinckrodt Pharmaceuticals announced it has entered into a research collaboration agreement with Transimmune AG, a company developing novel immunotherapies based on its unique…
Read More...

Titan Pharmaceuticals announced the execution of a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime that will expand patient access to treatment…
Read More...

Abbott and Novo Nordisk announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital…
Read More...

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT for the treatment of adults and children with…
Read More...

Xencor, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 1 study of XmAb14045, a CD123 x CD3 bispecific antibody molecule…
Read More...

Merck announced that the United States Patent and Trademark Office has issued a formal notice allowing Merck’s patent application directed to its proxy-CRISPR technology. “This is…
Read More...

Morphic Therapeutic announced that it has entered into a research and development collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop novel integrin therapeutics…
Read More...

QIAGEN N.V. announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V., to develop innovative bioinformatics and assay solutions to accelerate research targeting the…
Read More...

A new way to plan radiotherapy could help shape treatment away from sensitive organs near tumours to reduce side-effects, a new study shows. The technique has been developed by…
Read More...

BiomX Ltd. announced the closing of a $32 million series B equity financing. The financing was led by existing investors OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda…
Read More...